The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database

E. Raschi; C. Piccinni; E. Poluzzi; G. Marchesini; F. De Ponti

doi:10.1007/s00592-011-0340-7

journal article Oct 19, 2011

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database

E. Raschi C. Piccinni E. Poluzzi G. Marchesini F. De Ponti

Acta Diabetologica Vol. 50 No. 4 pp. 569-577 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/s00592-011-0340-7

Topics

No keywords indexed for this article. Browse by subject →

References

43

[1]

Lancashire RJ, Cheng K, Langman MJ (2003) Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. Aliment Pharmacol Ther 17:887–893 10.1046/j.1365-2036.2003.01485.x

[2]

Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S (2007) Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 5:648–661 10.1016/j.cgh.2006.11.023

[3]

Balani AR, Grendell JH (2008) Drug-induced pancreatitis: incidence, management and prevention. Drug Saf 31:823–837 10.2165/00002018-200831100-00002

[4]

Noel RA, Braun DK, Patterson RE, Bloomgren GL (2009) Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 32:834–838 10.2337/dc08-1755

[5]

Gonzalez-Perez A, Schlienger RG, Rodriguez LA (2010) Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care 33:2580–2585 10.2337/dc10-0842

[6]

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

C. J. Girman, T. D. Kou, B. Cai et al.

Diabetes, Obesity and Metabolism 2010 10.1111/j.1463-1326.2010.01231.x

[7]

Garg R, Chen W, Pendergrass M (2010) Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 33:2349–2354 10.2337/dc10-0482

[8]

Denker PS, Dimarco PE (2006) Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 29:471 10.2337/diacare.29.02.06.dc05-2043

[9]

Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A (2008) Exenatide and acute pancreatitis. J Assoc Physicians India 56:987–988

[10]

Ahmad SR, Swann J (2008) Exenatide and rare adverse events. N Engl J Med 358:1970–1971

[11]

US Food and Drug Administration (2007) Information for healthcare professionals: exenatide (marketed as Byetta)—10/2007. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124712.htm . Accessed 6 June 2011

[12]

US Food and Drug Administration (2008) Information for healthcare professionals: exenatide (marketed as Byetta)—8/2008 Update. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm079781.htm . Accessed 6 June 2011

[13]

US Food and Drug Administration (2009) Information for healthcare professionals—acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm183764.htm . Accessed 6 June 2011

[14]

Dore DD, Seeger JD, Arnold CK (2009) Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25:1019–1027 10.1185/03007990902820519

[15]

Engel SS, Williams-Herman DE, Golm GT, Clay RJ, Machotka SV, Kaufman KD, Goldstein BJ (2010) Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 64:984–990 10.1111/j.1742-1241.2010.02382.x

[16]

Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, Braun DK, Noel RA, Seeger JD (2011) A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 13:559–566 10.1111/j.1463-1326.2011.01376.x

[17]

Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150–156 10.1053/j.gastro.2011.02.018

[18]

Hawkes N (2011) Journal withdraws article after complaints from drug manufacturers. BMJ 342:d2335 10.1136/bmj.d2335

[19]

BMJ News (2011) Replies to “Journal withdraws article after complaints from drug manufacturers”. http://www.bmj.com/content/342/bmj.d2335.full/reply#bmj_el_256671 . Accessed 6 June 2011

[20]

European Association for the Study of Diabetes (2011) EASD commentary on the publication by Elashoff et al., published online in Gastroenterology, February 2011: Increased incidence of pancreatitis and cancer among patients given glucagon like peptide-1-based therapy. http://www.easd.org/easdwebfiles/statements/Elashoff_Commentary.pdf . Accessed 6 June 2011

[21]

US Food and Drug Administration (2011) The adverse event reporting system (AERS): latest quarterly data files. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ucm082193 . Accessed 6 June 2011

[22]

US Food and Drug Administration (2011) Drugs@FDA data files. http://www.fda.gov/Drugs/InformationOnDrugs/ucm079750.htm . Accessed 6 June 2011

[23]

EUROMEDSTAT (2007) A project funded by the European Union Commission. http://www.euromedstat.cnr.it/ . Accessed 6 June 2011

[24]

WHO Collaborating Centre for Drug Statistics Methodology (2010) ATC/DDD Index 2011. http://www.whocc.no/atc_ddd_index/ . Accessed 6 June 2011

[25]

Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F (2010) Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA adverse event reporting system. Drug Saf 33:303–314 10.2165/11531850-000000000-00000

[26]

Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427–436 10.1002/pds.1742

[27]

A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions

Eugéne P. van Puijenbroek, Andrew Bate, Hubert G. M. Leufkens et al.

Pharmacoepidemiology and Drug Safety 2002 10.1002/pds.668

[28]

De Bruin ML, van Puijenbroek EP, Egberts AC, Hoes AW, Leufkens HG (2002) Non-sedating antihistamine drugs and cardiac arrhythmias—biased risk estimates from spontaneous reporting systems? Br J Clin Pharmacol 53:370–374 10.1046/j.1365-2125.2002.01569.x

[29]

Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N (2007) Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 30:891–898 10.2165/00002018-200730100-00007

[30]

Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10:577–581 10.1002/sim.4780100409

[31]

Hauben M, Reich L, DeMicco J, Kim K (2007) ‘Extreme duplication’ in the US FDA adverse events reporting system database. Drug Saf 30:551–554 10.2165/00002018-200730060-00009

[32]

Piccinni C, Motola D, Marchesini G, Poluzzi E (2011) Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 34:1369–1371 10.2337/dc10-2412

[33]

Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a Pharmaco Vigilance database. Br J Clin Pharmacol. doi: 10.1111/j.1365-2125.2011.04037.x 10.1111/j.1365-2125.2011.04037.x

[34]

Hauben M, Hochberg A (2008) The importance of reporting negative findings in data mining. The example of exenatide and pancreatitis. Pharm Med 22:215–219 10.1007/bf03256706

[35]

Hartnell NR, Wilson JP (2004) Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 24:743–749 10.1592/phco.24.8.743.36068

[36]

Wang HW, Hochberg AM, Pearson RK, Hauben M (2010) An experimental investigation of masking in the US FDA adverse event reporting system database. Drug Saf 33:1117–1133 10.2165/11584390-000000000-00000

[37]

Amylin Pharmaceuticals Inc (2006) New or modified indication for exenatide. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021773s002,s006ltr.pdf . Accessed 6 June 2011

[38]

Begaud B, Moride Y, Tubert-Bitter P, Chaslerie A, Haramburu F (1994) False-positives in spontaneous reporting: should we worry about them? Br J Clin Pharmacol 38:401–404 10.1111/j.1365-2125.1994.tb04373.x

[39]

Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG (2011) Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 34:369–374 10.2337/dc10-1771

[40]

Mini-Sentinel (2011) Health outcomes details evidence review—pancreatitis. http://www.minisentinel.org/foundational_activities/related_projects/details.aspx?ID=125 . Accessed 10 June 2011

[41]

AIFA—Italian Medicines Agency (2011) Italian antidiabetic registry. http://antidiabetici.agenziafarmaco.it/ . Accessed 10 June 2011

[42]

Lee PH, Stockton MD, Franks AS (2011) Acute pancreatitis associated with liraglutide. Ann Pharmacother 45:e22 10.1345/aph.1p714

[43]

Girgis CM, Champion BL (2011) Vildagliptin-induced acute pancreatitis. Endocr Pract 17:e48–e50 10.4158/ep10383.cr

Metrics

82

Citations

43

References

Details

Published: Oct 19, 2011
Vol/Issue: 50(4)
Pages: 569-577
License: View

Authors

Cite This Article

E. Raschi, C. Piccinni, E. Poluzzi, et al. (2011). The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetologica, 50(4), 569-577. https://doi.org/10.1007/s00592-011-0340-7

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database

You May Also Like